48e3eab5-b82e-4dbb-88d2-e5cfe295fa88
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 57.0239561943874
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.540
- G2M_CHECKPOINT+0.520
- MYC_TARGETS_V1+0.440
- MYC_TARGETS_V2+0.430
- SPERMATOGENESIS+0.310
- UNFOLDED_PROTEIN_RESPONSE+0.310
- MTORC1_SIGNALING+0.300
- MITOTIC_SPINDLE+0.250
- OXIDATIVE_PHOSPHORYLATION+0.250
- INTERFERON_ALPHA_RESPONSE+0.210
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.390
- TGF_BETA_SIGNALING-0.380
- COAGULATION-0.320
- ESTROGEN_RESPONSE_EARLY-0.310
- KRAS_SIGNALING_UP-0.290
- UV_RESPONSE_DN-0.280
- ESTROGEN_RESPONSE_LATE-0.270
- P53_PATHWAY-0.270
- INFLAMMATORY_RESPONSE-0.260
- NOTCH_SIGNALING-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-58-A46M-01A-11R-A24H-07 | — | cohortSQ2 | 0.867 |
| 2 | SRR8518168 | — | E | 0.841 |
| 3 | TCGA-21-1083-01A-01R-0692-07 | — | cohortMD1 | 0.839 |
| 4 | SRR8518219 | — | E | 0.834 |
| 5 | GSM6454749 | — | F | 0.830 |
| 6 | 504282dd-4fef-4f70-a709-6a545d00a263 | — | — | 0.830 |
| 7 | TCGA-E2-A109-01A-11R-A10J-07 | — | B | 0.826 |
| 8 | SRR23303750 | — | — | 0.825 |
| 9 | TCGA-22-5481-01A-31R-1949-07 | — | cohortMD1 | 0.825 |
| 10 | 20020093.Her2HRneg | — | E | 0.817 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.520 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.430 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.310 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.310 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.250 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.210 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.210 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.090 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.090 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.070 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.060 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.060 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.050 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.030 | Inavolisib | — uncovered |